SCHEMBL2732862

SCHEMBL2732862

CCCCCCCCCCCCC/C=C/C=C/C=C(\O)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FASN P49327 1/20 0.61
ALDH1A1 P00352 1/20 0.53
TSHR P16473 1/20 0.53
FAAH O00519 3/20 0.51
KDM4E B2RXH2 1/20 0.51
TERT O14746 3/20 0.50
PTPN1 P18031 3/20 0.50
PPARG P37231 3/20 0.50
PPARD Q03181 3/20 0.50
PPARA Q07869 3/20 0.50
MAPT P10636 2/20 0.50
BLM P54132 2/20 0.50
HSD17B10 Q99714 2/20 0.50
FABP4 P15090 2/20 0.50
GMNN O75496 1/20 0.50
USP2 O75604 1/20 0.50
LMNA P02545 1/20 0.50
CYP1A2 P05177 1/20 0.50
POLB P06746 1/20 0.50
CYP2C9 P11712 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30000546 1.00 FASN (0.61) FASNALDH1A1TSHRFAAHKDM4E
SCHEMBL1427212 1.00 FASN (0.61) FASNALDH1A1TSHRFAAHKDM4E
SCHEMBL29253334 1.00 FASN (0.61) FASNALDH1A1TSHRFAAHKDM4E
SCHEMBL1427215 1.00 FASN (0.61) FASNALDH1A1TSHRFAAHKDM4E
SCHEMBL1055870 1.00 FASN (0.61) FASNALDH1A1TSHRFAAHKDM4E
SCHEMBL140063 1.00 FASN (0.61) FASNALDH1A1TSHRFAAHKDM4E
SCHEMBL1039992 1.00 FASN (0.61) FASNALDH1A1TSHRFAAHKDM4E
SCHEMBL140696 1.00 FASN (0.61) FASNALDH1A1TSHRFAAHKDM4E
SCHEMBL15048699 1.00 FASN (0.61) FASNALDH1A1TSHRFAAHKDM4E
SCHEMBL28614760 1.00 FASN (0.61) FASNALDH1A1TSHRFAAHKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118909698-A Method for simultaneously extracting water-soluble and fat-soluble essential oil of peony 三门峡牡仙生物科技有限公司 2024-11-08 CN claimed
CN-115768873-A Viable cell constructs for biosynthesizing dairy products, and products and methods related thereto 谢恩·吉利亚诺 2023-03-07 CN claimed
US-20230059978-A1 LIVE CELL CONSTRUCTS FOR BIOSYNTHETIC MILK PRODUCTION AND RELATED PRODUCTS AND METHODS GUILIANO SHAYNE (US) 2023-02-23 US claimed
EP-4087915-A1 LIVE CELL CONSTRUCTS FOR BIOSYNTHETIC MILK PRODUCTION AND RELATED PRODUCTS AND METHODS Guiliano, Shayne (US) 2022-11-16 EP claimed
WO-2021142241-A1 LIVE CELL CONSTRUCTS FOR BIOSYNTHETIC MILK PRODUCTION AND RELATED PRODUCTS AND METHODS GUILIANO SHAYNE (US) 2021-07-15 WO claimed
CN-122055135-A Cosmetic compositions and methods of use thereof 玫琳凯有限公司 2026-05-15 CN disclosed
US-20250345316-A1 METHODS OF INCREASING LYMPHOCYTE TRAFFICKING TO THE COLON BY STIMULATING RETINOIC ACID RECEPTORS AND ARYL HYDROCARBON RECEPTORS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2025-11-13 US disclosed
US-20250235422-A1 DODECA-2,4,6,8,10-PENTAENOIC ACID COMPOSITIONS AND USES THEREOF BIOMEDIT, INC. 2025-07-24 US disclosed
CN-120051283-A Nutraceutical compositions and methods of use thereof 玫琳凯有限公司 2025-05-27 CN disclosed
CN-119724395-A Oxidized fatty acid scale qualitative method based on non-targeted metabonomics 中国科学院大连化学物理研究所 2025-03-28 CN disclosed
CN-118909698-A Method for simultaneously extracting water-soluble and fat-soluble essential oil of peony 三门峡牡仙生物科技有限公司 2024-11-08 CN disclosed
CN-117849324-A Metabolism marker combination related to fight aggressive behavior, detection reagent and application 河南农业大学 2024-04-09 CN disclosed
WO-1999030620-A1 OPTOACOUSTIC CONTRAST AGENTS AND METHODS FOR THEIR USE IMARX PHARMACEUTICAL CORP. (US) 1999-06-24 WO disclosed
WO-1999013919-A1 NOVEL TARGETED CONTRAST AGENTS FOR DIAGNOSTIC AND THERAPEUTIC USE IMARX PHARMACEUTICAL CORP. (US) 1999-03-25 WO disclosed
EP-0901793-A1 Thermal preactivation of gaseous precursor filled compositions IMARX PHARMACEUTICAL CORP. (US) 1999-03-17 EP disclosed
WO-1998050040-A1 NOVEL LIPID SOLUBLE STEROID PRODRUGS IMARX PHARMACEUTICAL CORP. (US) 1998-11-12 WO disclosed
WO-1998050041-A1 NOVEL PRODRUGS COMPRISING FLUORINATED AMPHIPHILES IMARX PHARMACEUTICAL CORP. (US) 1998-11-12 WO disclosed
WO-1998048838-A1 COMPOUNDS NYCOMED IMAGING AS (NO) 1998-11-05 WO disclosed
EP-0831932-A1 NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE IMARX PHARMACEUTICAL CORP. (US) 1998-04-01 EP disclosed
WO-1996040285-A1 NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE IMARX PHARMACEUTICAL CORP. (US) 1996-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250235422-A1 DODECA-2,4,6,8,10-PENTAENOIC ACID COMPOSITIONS AND USES THEREOF CUTA, ALOX5AP, DAGLA FASN 626/4885ALDH1A1 616/4885TSHR 4799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.